COMPASS PATHWAYS PLC Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-05: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-05 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-13 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-15 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-15 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | We have adopted an Equity Award Grant Policy that sets forth the process for us to follow when we grant equity awards to our directors, executive officers and employees, including our advisors or consultants, pursuant to any of our equity compensation plans. Pursuant to the policy, all grants of equ… | |
| 2026-04-15 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | Currently, our general practice is to not take material nonpublic information into account when determining the timing and terms of an award and to not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. The Compensation and Leaders… | |
| 2026-04-15 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-15 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | Currently, our general practice is to not take material nonpublic information into account when determining the timing and terms of an award and to not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. | |
| 2026-04-15 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-04-15 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-15 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | PAY VERSUS PERFORMANCE The following table shows the total compensation for each of our principal executive officers (each a “PEO”) and the average compensation for our other named executive officers during the last three fiscal years ended December 31, 2025, 2024, and 2023 compared to our net incom… | |
| 2026-04-15 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | For fiscal 2025, our non-PEO named executive officers were Guy Goodwin and Teri Loxam. For fiscal 2024, our non-PEO named executive officers were Guy Goodwin, Teri Loxam and Matthew Owens. For fiscal 2023, our non-PEO named executive officers were Guy Goodwin, Matthew Owens, Ekaterina Malievskaia an… | |
| 2026-04-15 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | (2) The 2025 compensation actually paid to our PEO and the average compensation actually paid to our non-PEO named executives reflects the following adjustments from total compensation reported in the Summary Compensation Table: PEO Average of Non-PEO’s Total compensation reported in the Summary Com… | |
| 2026-04-15 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | (2) The 2025 compensation actually paid to our PEO and the average compensation actually paid to our non-PEO named executives reflects the following adjustments from total compensation reported in the Summary Compensation Table: PEO Average of Non-PEO’s Total compensation reported in the Summary Com… | |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: AggtChngPnsnValInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$1.04M |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: AggtChngPnsnValInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$280.75K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $1.86M |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $505.26K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $966.04K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $268.05K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $188.79K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $47.71K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $138.36K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $13.19K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: AggtChngPnsnValInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$3.41M |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: AggtChngPnsnValInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$1.20M |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $774.21K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $299.09K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$1.62M |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$213.29K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $254.79K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $42.93K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$178.38K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$14.64K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: AggtChngPnsnValInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | -$1.52M |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: AggtChngPnsnValInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$636.07K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $931.44K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $298.37K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $32.63K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $620.00 |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $74.71K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $74.71K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $26.90K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$11.28K |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $0.00 |
| 2026-04-15 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$54.60K |
| 2026-04-15 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | Compensation Actually Paid and Net Loss As a late-stage clinical biotechnology company primarily focused on research and development of novel treatments for serious mental health conditions, our company has not historically utilized net income (loss) as a performance measure for our executive compen… | |
| 2026-04-15 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | Compensation Actually Paid and TSR As shown in the following graph, from 2023 to 2024, the compensation actually paid to our named executive officers as a group (excluding our PEO) and our PEO decreased and our TSR decreased. From 2024 to 2025, our TSR increased and our compensation actually paid to… | |
| 2026-03-24 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |